1. Home
  2. CATY vs CELC Comparison

CATY vs CELC Comparison

Compare CATY & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cathay General Bancorp

CATY

Cathay General Bancorp

HOLD

Current Price

$47.33

Market Cap

3.4B

Sector

Finance

ML Signal

HOLD

Logo Celcuity Inc.

CELC

Celcuity Inc.

HOLD

Current Price

$113.68

Market Cap

3.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CATY
CELC
Founded
1962
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Medical Specialities
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.4B
3.1B
IPO Year
1996
2017

Fundamental Metrics

Financial Performance
Metric
CATY
CELC
Price
$47.33
$113.68
Analyst Decision
Buy
Strong Buy
Analyst Count
4
8
Target Price
$52.75
$106.63
AVG Volume (30 Days)
342.7K
527.9K
Earning Date
04-23-2026
01-01-0001
Dividend Yield
3.18%
N/A
EPS Growth
14.94
N/A
EPS
4.54
N/A
Revenue
$53,793,000.00
N/A
Revenue This Year
$20.37
N/A
Revenue Next Year
$5.41
N/A
P/E Ratio
$10.52
N/A
Revenue Growth
2.93
N/A
52 Week Low
$36.06
$7.58
52 Week High
$54.99
$120.32

Technical Indicators

Market Signals
Indicator
CATY
CELC
Relative Strength Index (RSI) 31.14 55.98
Support Level $44.58 $97.75
Resistance Level $49.21 $114.54
Average True Range (ATR) 1.36 5.14
MACD -0.43 0.36
Stochastic Oscillator 20.58 63.40

Price Performance

Historical Comparison
CATY
CELC

About CATY Cathay General Bancorp

Cathay General Bancorp is a regional bank predominantly serving the Chinese-American community. The company's policy is to reach out and actively offer services to low-to-moderate income groups in the delineated branch service areas. It predominantly provides services such as checking and deposit, lines of credits, commercial and commercial real estate loans, merchant services and payment processing, treasury management services, international banking and financing services, and other customary banking services to individuals, professionals, and small to medium-sized businesses. Through its Wealth Management unit, the company also offers investment products and services, such as stocks, bonds, mutual funds, insurance, annuities and advisory services.

About CELC Celcuity Inc.

Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.

Share on Social Networks: